학술논문
Comparative Study of Ciprofloxacin (BAY o 9867) and Pipemidic Acid in the Treatment for Suppurative Otitis Media / 化膿性中耳炎に対するCiprofloxadn (BAYo9867) とPipemidicacidの薬効比較試験
Document Type
Journal Article
Author
Akimasa NAKAMURA; Akira IIO; Akiteru YUMISAKI; Atsushi SHINKAWA; Daisuke CHIKUIE; Eriko TABUCHI; Eriko TOMOMATSU; Etsuro OBATA; Fumikazu MIZUKOSHI; Goro MOGI; Hajime MAEDA; Haruhiro HAYASHI; Haruhisa HORIKAWA; Haruji KINOSHITA; Haruo ITO; Hideharu ARUGA; Hideki KIDA; Hideki WADA; Hirofumi MATSUYAMA; Hiromitsu TAMAKI; Hirosato MIYAKE; Hiroshi SAIKA; Hiroshi WATANABE; Hitoshi OGINO; Ichiro MORIYAMA; Ikuo OHNO; Jun HONDO; Jun MORIMOTO; Junichi MATSUKAWA; Junichiro SHIMADA; Junko ISHII; Kaoru SOYANO; Kazuaki OGAWA; Kazue UENO; Kei OGAWA; Keiichi DATE; Ken MUKAI; Kenji MURANO; Kenji SUZUKI; Kenji WADA; Koichi SHIBUI; Koji YAJIN; Kozo FUKAMIZU; Kunihiko SAKAMOTO; Makoto HASHIMOTO; Makoto SAKAI; Mamoru TSUDA; Masahiro HIRAKAWA; Masahiro IIDA; Masakaze NAKATA; Masao TSUKIYAMA; Masaru OHYAMA; Masayoshi OZAKI; Masayoshi TACHIBANA; Mashiko ANDO; Masuhiro NODA; Michinori KUROKAWA; Mikiko TAKAYAMA; Minoru ISHIDA; Mitsuaki INAGAKI; Mitsuyoshi NAKAJIMA; Miwa HYUGA; Mutsumi NAKAYAMA; Naozo TAYA; Nobuharu TAGASHIRA; Nobukazu TADAKI; Nobuyuki KOMATSU; Osamu MIZUKOSHI; Ryoto OHYA; Ryuji KATAOKA; Ryuji KIYOTA; Saburo MIMAKI; Satoru TAKENOUCHO; Satoshi OHNO; Shigeaki SAITO; Shigeru FURUTA; Shigeru MIYOSHI; Shimei KAN; Shinichi OKUMURA; Shinji KATO; Shoji SAITO; Shozo KAWAMURA; Shubun TAKEBAYASHI; Shunkichi BABA; Tadashi AKITAYA; Takashi KAWAI; Takashi MATSUI; Takatsugu ITABASHI; Takeshi MARUO; Takeshige NISHIMURA; Takuo MAEYAMA; Tetsuo ISHII; Tomohiro YASUNO; Toru MATSUNAGA; Tsutomu HATANO; Tsuyoshi TAKANO; Yasuji INOUE; Yasuo HARADA; Yoshiaki HIRASUGI; Yoshito MORI; Yoshiyuki TAMURA; Yuichi KURONO; Yuko NINOMIYA; Yuriko SUITSU; Yutaka FUJIMAKI; Yuzuru MURAKAMI; 三好 茂; 三宅 浩郷; 三牧 三郎; 上野 一恵; 中山 むつみ; 中島 光好; 中村 明正; 中田 将風; 丸尾 猛; 二宮 優子; 井上 靖二; 伊藤 晴夫; 伊達 敬一; 前山 拓夫; 前田 一; 加藤 眞二; 原田 康夫; 友松 えり子; 古田 茂; 只木 信和; 向井 研; 和田 健二; 和田 秀毅; 坂井 真; 坂本 邦彦; 堀川 治久; 夜陣 紘治; 大山 勝; 大矢 良人; 大野 聖; 大野 郁夫; 奥村 新一; 安藤 真姿子; 安野 友博; 小川 和昭; 小川 敬; 小幡 悦朗; 小松 信行; 尾崎 正義; 島田 純一郎; 平川 勝洋; 平杉 嘉昭; 弓崎 明輝; 征矢野 薫; 斎藤 彰治; 斎藤 成明; 新川 敦; 日向 美和; 月山 昌夫; 有賀 秀治; 木下 治二; 本堂 潤; 村上 譲; 村野 健二; 松井 隆史; 松山 博文; 松川 純一; 松永 亨; 板橋 隆嗣; 林 治博; 森 慶人; 森山 一郎; 森本 純; 橋本 真実; 橘正 芳; 水津 百合子; 水越 文和; 水越 治; 河合 窄; 河村 正三; 波多野 努; 津田 守; 深水 浩三; 清田 隆二; 渋井 弘一; 渡辺 洋; 片岡 隆嗣; 玉置 弘光; 田村 嘉之; 田淵 えり子; 田矢 直三; 田頭 宣治; 石井 哲夫; 石井 純子; 石田 稔; 秋田谷 直; 稲垣 光昭; 竹之内 智; 竹林 脩文; 築家 大介; 簡 志明; 茂木 五郎; 荻野 仁; 藤巻 豊; 西村 武重; 貴田 秀樹; 野田 益弘; 鈴木 賢二; 雑賀 宏; 飯尾 明; 飯田 政弘; 馬場 俊吉; 高山 幹子; 高野 剛; 黒川 道徳; 黒野 祐一
Source
耳鼻と臨床 / jibi to rinsho. 1987, 33(1):100
Subject
Language
Japanese
ISSN
0447-7227
2185-1034
2185-1034
Abstract
The clinical effectiveness, safety and utility of Ciprofloxacin (CPFX) in the treatment of patients with suppurative otitis media were compared with patients treated with Pipemidic acid (PPA) in a double-blind study. Patients of 15 years of age or over with acute suppurative otitis media, acute exacerbation of chronic suppurative otitis media, and chronic suppurative otitis media were administered either 600 mg of CPFX or 2g of PPA orally for 7 days. PPA is not indicated for gram positive infection. The following results were obtained. 1. The clinical efficacy rate according to doctors in charge of the cases was 63.8 % (83/130) in the CPFX group and 56.6 % (69/122) in the PPA group. A higher efficacy rate was observed in the CPFX group (p<0.1). In the patients with monomicrobial infec- tions, the CPFX group showed a higher efficacy rate (p<0.1), while in the patients with polymicrobial infections, there was no significant difference between the two groups. The clinical efficacy rate in the CPFX group was higher than that of the PPA group in patients with polymicrobial infections of gram positive bacteria (GPB)(p<0.05). In the patients with polymicrobial infections with GPB plus gram negative bacteria (GNB), the rate for the PPA group was higher than that of CPFX group (p<0.05). In the patients with monomicrobial infections with GPB or GNB or polymicrobial infections with GNB, there was no significant difference between the two groups. 2. On the basis of a committee judgement, the clinical efficacy rates in all the cases were 60.3 % (79/131) in the CPFX group and 50.8 % (62/122) in the PPA group. The difference between the two groups was not significant. In patients with polymicrobial infections with GPB, the efficacy rate in the CPFX group was higher than that in the PPA group (p<0.05). A higher rate of the cases with excellent effects was observed in the PPA group in polymicrobial infections with GPB plus GNB (p<0.1). No difference was seen in monomicrobial infections with GPB or GNB or polymicrobial infections with GNB. 3. As for bacteriological effects, the eradication rates in the total cases were 60.9 % (70/115) in the CPFX group and 54.6% (59/108) in the group. The difference was not significant. In patients with polymicrobial infection with GPB, a higher eradication rate was observed in the CPFX group (p<0.1). In the patients with monomicrobial infections with GPB or GNB or polymicrobial infections with GNB or GPB plus GNB, there was no significant difference. 4. Side effects were noted in 5 of 138 cases (3.6%) treated with CPFX and in 10 of 140 cases (7.1 %) treated with PPA. The difference was not statistically significant. 5. The utility rates by doctors in charge of the cases were 67.9 % (89/131) in the CPFX group and 55.7% (68/122) in the PPA group, respectively. The difference was statistically significant (p<0.05). In patients with acute exacerbation of chronic otitis media, moderately severe infection, both monomicrobial infection, and polymicrobial infection with GPB or GNB, the utility rates of CPFX group were higher than those of the PPA group (p<0.05). In monomicrobial infections with GPB or GNB, the CPFX group showed a trend of a higher rate of utility (p<0.1). From these results, it was concluded that CPFX was very useful drug in the treatment of suppurative otitis media caused by gram positive or negative bacteria at a dose approximately 1/3 that of PPA.